Living donor liver transplantation for hepatocellular carcinoma: results of prospective patient selection by Kyushu University Criteria in 7 years

Hideaki Uchiyama, Shinji Itoh, Tomoharu Yoshizumi, Toru Ikegami, Norifumi Harimoto, Yuji Soejima, Noboru Harada, Kazutoyo Morita, Takeo Toshima, Takashi Motomura, Yoshihiko Maehara

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background Expanding patient selection beyond the Milan criteria in living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC) has long been a matter for debate. We have used the Kyushu University Criteria – maximum tumor diameter <5 cm or des-γ-carboxy prothrombin <300 mAU/ml – in LDLT for HCC since June 2007. The aim of the present study was to present the results of our prospective patient selection by Kyushu University Criteria and to confirm whether or not our criteria were justified. Methods The entire study period was divided into the pre-Kyushu era (July 1999–May 2007) and the Kyushu era (June 2007–November 2014). Eighty-nine and 90 patients underwent LDLT for HCC in the pre-Kyushu era and the Kyushu era, respectively. Results In the pre-Kyushu era, there were significant differences in recurrence-free and disease-specific survival between the beyond-Milan and the within-Milan patients. In the Kyushu era, however, the differences in recurrence-free and disease-specific survival between the beyond-Milan and the within-Milan patients disappeared. The 5-year overall patient survival in the Kyushu era was 89.4%. Conclusion Our selection criteria enabled a considerable number of beyond-Milan patients to undergo LDLT without jeopardizing the recurrence-free, and disease-specific, and overall patient survival.

Original languageEnglish
Pages (from-to)1082-1090
Number of pages9
JournalHPB
Volume19
Issue number12
DOIs
Publication statusPublished - Dec 2017

Fingerprint

Living Donors
Liver Transplantation
Patient Selection
Hepatocellular Carcinoma
Recurrence
Disease-Free Survival
Survival
Prothrombin
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Living donor liver transplantation for hepatocellular carcinoma : results of prospective patient selection by Kyushu University Criteria in 7 years. / Uchiyama, Hideaki; Itoh, Shinji; Yoshizumi, Tomoharu; Ikegami, Toru; Harimoto, Norifumi; Soejima, Yuji; Harada, Noboru; Morita, Kazutoyo; Toshima, Takeo; Motomura, Takashi; Maehara, Yoshihiko.

In: HPB, Vol. 19, No. 12, 12.2017, p. 1082-1090.

Research output: Contribution to journalArticle

Uchiyama, Hideaki ; Itoh, Shinji ; Yoshizumi, Tomoharu ; Ikegami, Toru ; Harimoto, Norifumi ; Soejima, Yuji ; Harada, Noboru ; Morita, Kazutoyo ; Toshima, Takeo ; Motomura, Takashi ; Maehara, Yoshihiko. / Living donor liver transplantation for hepatocellular carcinoma : results of prospective patient selection by Kyushu University Criteria in 7 years. In: HPB. 2017 ; Vol. 19, No. 12. pp. 1082-1090.
@article{ef98d57fbc894ad78663617b0b3e049b,
title = "Living donor liver transplantation for hepatocellular carcinoma: results of prospective patient selection by Kyushu University Criteria in 7 years",
abstract = "Background Expanding patient selection beyond the Milan criteria in living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC) has long been a matter for debate. We have used the Kyushu University Criteria – maximum tumor diameter <5 cm or des-γ-carboxy prothrombin <300 mAU/ml – in LDLT for HCC since June 2007. The aim of the present study was to present the results of our prospective patient selection by Kyushu University Criteria and to confirm whether or not our criteria were justified. Methods The entire study period was divided into the pre-Kyushu era (July 1999–May 2007) and the Kyushu era (June 2007–November 2014). Eighty-nine and 90 patients underwent LDLT for HCC in the pre-Kyushu era and the Kyushu era, respectively. Results In the pre-Kyushu era, there were significant differences in recurrence-free and disease-specific survival between the beyond-Milan and the within-Milan patients. In the Kyushu era, however, the differences in recurrence-free and disease-specific survival between the beyond-Milan and the within-Milan patients disappeared. The 5-year overall patient survival in the Kyushu era was 89.4{\%}. Conclusion Our selection criteria enabled a considerable number of beyond-Milan patients to undergo LDLT without jeopardizing the recurrence-free, and disease-specific, and overall patient survival.",
author = "Hideaki Uchiyama and Shinji Itoh and Tomoharu Yoshizumi and Toru Ikegami and Norifumi Harimoto and Yuji Soejima and Noboru Harada and Kazutoyo Morita and Takeo Toshima and Takashi Motomura and Yoshihiko Maehara",
year = "2017",
month = "12",
doi = "10.1016/j.hpb.2017.08.004",
language = "English",
volume = "19",
pages = "1082--1090",
journal = "HPB",
issn = "1365-182X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Living donor liver transplantation for hepatocellular carcinoma

T2 - results of prospective patient selection by Kyushu University Criteria in 7 years

AU - Uchiyama, Hideaki

AU - Itoh, Shinji

AU - Yoshizumi, Tomoharu

AU - Ikegami, Toru

AU - Harimoto, Norifumi

AU - Soejima, Yuji

AU - Harada, Noboru

AU - Morita, Kazutoyo

AU - Toshima, Takeo

AU - Motomura, Takashi

AU - Maehara, Yoshihiko

PY - 2017/12

Y1 - 2017/12

N2 - Background Expanding patient selection beyond the Milan criteria in living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC) has long been a matter for debate. We have used the Kyushu University Criteria – maximum tumor diameter <5 cm or des-γ-carboxy prothrombin <300 mAU/ml – in LDLT for HCC since June 2007. The aim of the present study was to present the results of our prospective patient selection by Kyushu University Criteria and to confirm whether or not our criteria were justified. Methods The entire study period was divided into the pre-Kyushu era (July 1999–May 2007) and the Kyushu era (June 2007–November 2014). Eighty-nine and 90 patients underwent LDLT for HCC in the pre-Kyushu era and the Kyushu era, respectively. Results In the pre-Kyushu era, there were significant differences in recurrence-free and disease-specific survival between the beyond-Milan and the within-Milan patients. In the Kyushu era, however, the differences in recurrence-free and disease-specific survival between the beyond-Milan and the within-Milan patients disappeared. The 5-year overall patient survival in the Kyushu era was 89.4%. Conclusion Our selection criteria enabled a considerable number of beyond-Milan patients to undergo LDLT without jeopardizing the recurrence-free, and disease-specific, and overall patient survival.

AB - Background Expanding patient selection beyond the Milan criteria in living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC) has long been a matter for debate. We have used the Kyushu University Criteria – maximum tumor diameter <5 cm or des-γ-carboxy prothrombin <300 mAU/ml – in LDLT for HCC since June 2007. The aim of the present study was to present the results of our prospective patient selection by Kyushu University Criteria and to confirm whether or not our criteria were justified. Methods The entire study period was divided into the pre-Kyushu era (July 1999–May 2007) and the Kyushu era (June 2007–November 2014). Eighty-nine and 90 patients underwent LDLT for HCC in the pre-Kyushu era and the Kyushu era, respectively. Results In the pre-Kyushu era, there were significant differences in recurrence-free and disease-specific survival between the beyond-Milan and the within-Milan patients. In the Kyushu era, however, the differences in recurrence-free and disease-specific survival between the beyond-Milan and the within-Milan patients disappeared. The 5-year overall patient survival in the Kyushu era was 89.4%. Conclusion Our selection criteria enabled a considerable number of beyond-Milan patients to undergo LDLT without jeopardizing the recurrence-free, and disease-specific, and overall patient survival.

UR - http://www.scopus.com/inward/record.url?scp=85030864352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030864352&partnerID=8YFLogxK

U2 - 10.1016/j.hpb.2017.08.004

DO - 10.1016/j.hpb.2017.08.004

M3 - Article

C2 - 28888776

AN - SCOPUS:85030864352

VL - 19

SP - 1082

EP - 1090

JO - HPB

JF - HPB

SN - 1365-182X

IS - 12

ER -